Search research articles
Contact Us
Filters
Showing results (101-110 of 126) with videos related to
Page
of 13
Sort By:
Nature Communications
|
April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Clinical Genitourinary Cancer
|
December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>
Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
Nature Communications
|
July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Medicine
|
August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer
|
January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial
Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Medicine
|
August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Cancer Discovery
|
April 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study
Salah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, et al.
Nature Medicine
|
April 22, 2024
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Medicine
|
March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 126) with videos related to
Sort By:
Page
of 13
Nature Communications
|
April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Clinical Genitourinary Cancer
|
December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>
Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
Nature Communications
|
July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Medicine
|
August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer
|
January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial
Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Medicine
|
August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Cancer Discovery
|
April 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study
Salah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, et al.
Nature Medicine
|
April 22, 2024
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Medicine
|
March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
Page
of 13